Table 1.
Patient characteristics
| Characteristics | Patients (n) (N=577) | % |
| TKI agent | ||
| Gefitinib | 529 | 91.7 |
| Erlotinib | 48 | 8.3 |
| Sex | ||
| Men/women | 177/400 | 30.7/69.3 |
| Age (years) | ||
| Median | 69 | |
| Range | 27–93 | |
| PS | ||
| 0 | 188 | 32.6 |
| 1 | 246 | 42.6 |
| 2 | 84 | 14.6 |
| 3 | 45 | 7.8 |
| 4 | 11 | 1.9 |
| Unknown | 3 | 0.5 |
| Stage | ||
| IIIA | 8 | 1.6 |
| IIIB | 18 | 3.7 |
| IV | 466 | 94.7 |
| Site of metastasis | ||
| Bone | 253 | 23.1 |
| Lung | 240 | 22.0 |
| Brain | 171 | 15.6 |
| Liver | 60 | 5.5 |
| Histology | ||
| Adenocarcinoma | 567 | 98.3 |
| NSCLC (not otherwise specified) | 7 | 1.2 |
| Other | 3 | 0.5 |
| EGFR mutation subtype | ||
| Exon 19 deletion | 279 | 48.4 |
| Exon 21 L858R | 274 | 47.5 |
| Other | 24 | 4.2 |
| Smoking status | ||
| Never smoked | 381 | 66.0 |
| Current smoker | 42 | 7.3 |
| Previous smoker | 152 | 26.3 |
| Unknown | 2 | 0.4 |
| Comorbidity | ||
| COPD | 22 | 3.8 |
| Hepatic disease | 7 | 1.2 |
| Interstitial lung disease | 3 | 0.5 |
| None of the above | 545 | 94.5 |
| Previous treatment | ||
| None | 396 | 68.6 |
| Surgery | 60 | 10.4 |
| Radiation | 101 | 17.5 |
| Surgery+radiation | 20 | 3.5 |
COPD, chronic obstructive pulmonary disease; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung carcinoma; PS, performance status; TKI, tyrosine kinase inhibitor.